Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

181
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
181
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

136
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
136
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Comparing Survival Of Older Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy Versus Primary Cytoreductive Surgery: Reducing Bias Through Machine Learning

Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning

Yongmei Huang1, J Alejandro Rauh-Hain2, Thomas H McCoy3

  • 1Columbia University Vagelos College of Physicians and Surgeons, Department of Obstetrics and Gynecology, United States of America.

Gynecologic Oncology
|March 30, 2024

Related Experiment Videos

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

261
Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

6.8K

View abstract on PubMed

Summary
This summary is machine-generated.

A new Multidimensional Comorbidity Index (MCI) more accurately predicts early mortality in ovarian cancer patients than the Charlson Comorbidity Index (CCI). The MCI also reduces confounding in treatment comparisons, improving health services research.

Area of Science:

  • Oncology
  • Health Services Research
  • Biostatistics

Background:

  • Accurate comorbidity assessment is crucial for ovarian cancer patient care and research.
  • Existing indices like the Charlson Comorbidity Index (CCI) may not fully capture comorbidity burden in ovarian cancer.
  • Health services research requires reliable tools to adjust for baseline health status in comparative effectiveness studies.

Purpose of the Study:

  • To develop and validate a Multidimensional Comorbidity Index (MCI) for ovarian cancer.
  • To compare the accuracy of the MCI against the CCI in predicting 1-year mortality.
  • To evaluate the MCI's utility in reducing confounding in comparative effectiveness research, specifically regarding neoadjuvant chemotherapy (NACT).

Main Methods:

  • Utilized SEER-Medicare data for patients with stage IIIC/IV ovarian cancer (2010-2015).
Keywords:
All-cause mortalityMachine learningMultidimensional comorbidity indexNeoadjuvant chemotherapy

Related Experiment Videos

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

261
Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

6.8K
  • Employed partial least squares regression, a machine learning algorithm, to develop the MCI using pre-diagnosis claims and 1-year mortality.
  • Assessed MCI and CCI performance (discrimination and calibration) for 1-year mortality and evaluated confounding reduction in NACT vs. primary surgery analysis.

    • Main Results:

    • The MCI showed superior discrimination for 1-year mortality (c-index: 0.75) compared to the CCI (c-index: 0.59).
    • MCI demonstrated better calibration between predicted and observed mortality risk.
    • Controlling for MCI, not CCI, eliminated the significant association between NACT and increased 1-year mortality.

    Conclusions:

    • The MCI is a more accurate predictor of 1-year mortality in ovarian cancer patients than the CCI.
    • The MCI effectively reduces confounding in comparative effectiveness research, particularly for treatments like NACT.
    • The MCI offers an improved tool for health services research involving ovarian cancer patients.
    Primary cytoreductive surgery